Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer

Nature Medicine volume 27, pages 1339–1341 (2021)Cite this article

Subjects

A phase 1 trial shows promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non–small-cell lung cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Procedure for the generation of TILs for adoptive cell-transfer therapy.

References

  1. Sharma, P. & Allison, J. P. Nat. Rev. Immunol. 20, 75–76 (2020).

    Article  CAS  Google Scholar 

  2. Dudley, M. E. et al. J. Clin. Oncol. 26, 5233–5239 (2008).

    Article  CAS  Google Scholar 

  3. Stevanovic, S. et al. Clin. Cancer Res. 25, 1486–1493 (2019).

    Article  CAS  Google Scholar 

  4. Tran, E. et al. Science 344, 641–645 (2014).

    Article  CAS  Google Scholar 

  5. Tran, E. et al. N. Engl. J. Med. 375, 2255–2262 (2016).

    Article  CAS  Google Scholar 

  6. Zacharakis, N. et al. Nat. Med. 24, 724–730 (2018).

    Article  CAS  Google Scholar 

  7. Creelan, B. C. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01462-y (2021).

    Article  Google Scholar 

  8. Ghorani, E. et al. Nat. Can. 1, 546–561 (2020).

    Article  Google Scholar 

  9. Muranski, P. et al. Nat. Clin. Pract. Oncol. 3, 668–681 (2006).

    Article  CAS  Google Scholar 

  10. Siddiqui, I. et al. Immunity 50, 195–211.e110 (2019).

    Article  CAS  Google Scholar 

  11. Krishna, S. et al. Science 370, 1328–1334 (2020).

    Article  CAS  Google Scholar 

  12. Alspach, E. et al. Nature 574, 696–701 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Joshua R. Veatch, Sylvain Simon & Stanley R. Riddell

  2. University of Washington, Seattle, WA, USA

    Joshua R. Veatch & Stanley R. Riddell

Authors
  1. Joshua R. Veatch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvain Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley R. Riddell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley R. Riddell.

Ethics declarations

Competing interests

S.R.R. holds equity in and consults for Lyell Immunopharma and Adaptive Biotechnologies. S.R.R. is an inventor of patents licensed to Bristol Myers Squibb, and S.R.R. and J.R.V. are inventors on intellectual property that is licensed to Lyell Immunopharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Veatch, J.R., Simon, S. & Riddell, S.R. Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer. Nat Med 27, 1339–1341 (2021). https://doi.org/10.1038/s41591-021-01445-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01445-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing